Design, Formulation Development and Characterization of Transdermal Patches Loaded with Pseudoephedrine and Loratadine

ABSTARCT Objective The purpose of this study was to develop the transdermal patch with a combination of pseudoephedrine HCL and Loratadine . Methodology Various formulations of these anti-anthetic drugs were prepared using Eudragit RL100 as primary polymer. Ethyl cellulose (EC), twin 80, isopropyl myristate (IPM), Propylene Glycol (PG), and Span 20 were included as those who enhance transit. The finished patch was evaluated to their visual properties, including clarity, smoothness and brittleness. Additionally, thickness, pharmaceutical content, Fourier transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD) were performed. Drug release was evaluated through in vitro disintegration studies, and evaluated using a USP Dissolution apparatus. Results The results demonstrated that the choice of enhancers affected drug release and transit profiles. The patch made with castor oil displayed the lowest levels of drug release and transit for both pseudoephedrine HCL and Loratadine (56.37% PSE and 54.37% LT). In contrast, the formulation with isopropyl myristate showed the highest level of drug release and permit.(62.42% PSE and 59.37% LT) at the end of 12 hours in vitro dissolution study. Physicochemical characterization was found stable. Conclusion These findings indicate that a transdermal patch is possible to combine pseudoephedrine HCL and Loratadine drugs can be suitably developed as an alternate to conventional dosage forms. Whereas its release studies showed for both drugs can be effectively dependent by selecting proper enhancers.